BUY
An exciting stock. Have done a recent financing. Waiting for FDA approval. Getting geared up for sales in the states. Speculative.
BUY
45% of their sales goes to Nortel and 20% to Ericsson, both on the wireless side. Recently got a new contract. Expects the big traction towards the end of the year.
WATCH
Ranks in the bottom 7% of the database. Guidance on sales has been downward. Earnings estimates have dropped 23%. New management should turn things around.
DON'T BUY
Recent earnings were better than expected, but estimates have dropped recently. Have cash of about $.70 per share. Competition is offering a similar product for free.
DON'T BUY
Ranks very well in their database model. Earnings estimates have drifted up about 4% in the last 90 days. Have some new products. Some analysts do not feel the picture is as rosy as it would appear.
BUY

Trades in a band of $.40 to $.50. They have a methodology which should be quite powerful for them in 2004. Have a one-year lead over Pfizer. Speculative but pretty good prospects.

BUY
Sales are up 80%. Getting a very large reception from hospitals. Have strong expectations.
PAST TOP PICK
(A top pick Nov 21/03. Up 45%.) Thinks there is still very good opportunity for this company.
PAST TOP PICK
(A top pick Nov 21/03. Down 15%.) Expects it to go sideways for the next 6/8 months. Still keep and feels the outlook is good.
PAST TOP PICK
(A top pick Nov 21/03. Up 15%.) Still thinks they're very good opportunities for this company.
DON'T BUY
Ranks borderline on the bottom third of the database. Earnings estimates have dropped 5%. Worried about Intel as competition.
DON'T BUY
Has interesting technology and has talked about a patent on their RFD system. Feels that it is grossly overvalued. Prefers EXI Wireless.
DON'T BUY
Ranks borderline of the top quarter of the database. Year-over-year earnings and sales are down about 10%.
WAIT
Ranks in the bottom 10% of the database. Earnings are slightly up, but sales are down about 16%. Maybe working on some very interesting technology over the next 90 days. Very speculative.
DON'T BUY
Ranks in the bottom 10% of the database. Analyst has chopped earnings as they are focusing on R&D. Getting new contracts. Will do more analysis as to whether they sell their shares.